for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Krystal Biotech Inc

KRYS.O

Latest Trade

55.29USD

Change

-0.82(-1.46%)

Volume

265,995

Today's Range

54.21

 - 

58.80

52 Week Range

38.86

 - 

102.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
56.11
Open
55.28
Volume
265,995
3M AVG Volume
9.46
Today's High
58.80
Today's Low
54.21
52 Week High
102.99
52 Week Low
38.86
Shares Out (MIL)
24.91
Market Cap (MIL)
1,397.49
Forward P/E
-19.83
Dividend (Yield %)
--

Next Event

Q4 2021 Krystal Biotech Inc Earnings Release

Latest Developments

More

Krystal Biotech Announces Pricing Of $200 Million Public Offering Of Common Stock

Krystal Biotech Announces Proposed $200 Million Public Offering Of Common Stock

Krystal Biotech Announces Topline Results From GEM-3 Pivotal Trial Of Vyjuvek In Patients With Dystrophic Epidermolysis Bullosa

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Krystal Biotech Inc

Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Industry

Biotechnology & Drugs

Contact Info

2100 Wharton St Ste 701

PITTSBURGH, PA

15203-1973

United States

+1.412.5865830

https://www.krystalbio.com/

Executive Leadership

Krish S. Krishnan

Chairman of the Board, President, Chief Executive Officer

Suma M. Krishnan

Founder, Chief Operating Officer, Director

Bhushan Hardas

President - Jeune, Inc

Kathryn A. Romano

Chief Accounting Officer

Jing L. Marantz

Chief Business Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.970

2019

-1.200

2020

-1.710

2021(E)

-2.830
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-16.16
Return on Equity (TTM)
-15.25

Latest News

Latest News

BRIEF-Krystal Biotech Announces Pricing Of $125 Mln Public Offering Of Common Stock

* KRYSTAL BIOTECH ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Krystal Biotech Announces Proposed Public Offering Of Common Stock

* KRYSTAL BIOTECH ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Krystal Biotech Says Phase 2 Study In 4-6 Pediatric Patients Anticipated To Start In H2 2020

* KRYSTAL BIOTECH ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1/2 CLINICAL TRIAL OF KB105 IN PATIENTS WITH TGM1-RELATED AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS (ARCI)

BRIEF-Krystal Biotech Inc Files For Potential Mixed Shelf Offering; Size Not Disclosed

* KRYSTAL BIOTECH INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text - https://bit.ly/3c3YqqP Further company coverage:

BRIEF-Krystal Biotech Reports 2019 Financial Results And Business Progress

* KRYSTAL BIOTECH REPORTS 2019 FINANCIAL RESULTS AND BUSINESS PROGRESS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up